MNOV · Medicinova Inc
$1.48
-0.09 (-5.73%)
At close · Aug 26
Market Cap
$73.34M
Shares
49.22M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$409.66K
FY2025
Net Income
-$12M
-8.6%
FY2025
Operating Margin
-3242.47%
FY2025
Diluted EPS
-$0.24
-4.3%
FY2025
Operating Cash Flow
-$9.81M
+7.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 | FY2006 | FY2005 | FY2004 | FY2003 | FY2002 | FY2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $409.66K | — | $1M | — | $4.04M | — | — | — | — | — | — | — | — | $802.58K | — | — | — | — | — | — | — | — | — | — | — | |
| $5.1M | $6.7M | $6.8M | $5.3M | $8.7M | $8.1M | $7.1M | $5.7M | $5.3M | $3.9M | $3.1M | $2.7M | $2.9M | $2.7M | $4.5M | $7.78M | $9.71M | $10.87M | — | — | — | — | — | — | — | — | |
| $6.78M | $6.16M | $5.48M | $5.24M | $5.48M | $5.72M | $6.69M | $7.95M | $9.96M | $8.8M | $7.36M | $5.81M | $5.96M | $6.66M | $6.73M | $8.32M | $8.17M | $10.37M | — | — | — | — | — | — | — | — | |
| — | $20.1K | $21.08K | $20.3K | $17.71K | $26.15K | $21.34K | $23.94K | $25.88K | $28.1K | $14.13K | $26.7K | $40.19K | $100.49K | $69.53K | $41.87K | $108.26K | $219.2K | — | — | — | — | — | — | — | — | |
| $12.77M | $13.69M | $12.68M | $10.9M | $14.63M | $14.25M | $14.18M | $14.03M | $15.59M | $13.03M | $10.88M | $8.82M | $9.22M | $10.02M | $11.75M | $16.11M | $17.88M | $21.24M | — | — | — | — | — | — | — | — | |
| -$11.85M | -$13.28M | -$12.68M | -$9.9M | -$14.63M | -$10.22M | -$14.18M | -$14.03M | -$15.59M | -$13.03M | -$10.88M | -$8.82M | -$9.22M | -$4.02M | -$10.95M | -$16.11M | -$17.88M | -$21.24M | — | — | — | — | — | — | — | — | |
| — | -3242.47% | — | -990.03% | — | -253.02% | — | — | — | — | — | — | — | — | -1363.77% | — | — | — | — | — | — | — | — | — | — | — | |
| — | -$13.26M | -$12.65M | -$9.88M | -$14.61M | -$10.19M | -$14.16M | -$14.01M | -$15.56M | -$13M | -$10.87M | -$8.8M | -$9.18M | -$3.92M | -$10.88M | -$16.07M | -$17.77M | -$21.02M | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | $298 | $454 | $514 | $628 | — | — | $1.6M | $1.77M | $242.37K | — | — | — | — | — | — | — | — | |
| -$24.28K | -$12.75K | -$39.49K | -$502.87K | -$247.29K | -$59.5K | -$38.4K | -$46.16K | -$22.89K | -$25.6K | -$47.04K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | $19.87K | -$1673 | -$32.14K | -$34.32K | $3807 | $13.78K | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | -$11.99M | -$11.04M | -$8.57M | -$14.07M | -$10.13M | -$13.86M | -$12.93M | -$14.67M | -$12.91M | -$10.86M | -$8.84M | -$9.2M | -$4.02M | -$10.95M | -$17.72M | -$20.17M | -$20.36M | — | — | — | — | — | — | — | — | |
| — | $5994 | $5537 | $3047 | $2822 | $2568 | -$1648 | $12.66K | $5276 | -$1.74M | $3754 | $7359 | -$3972 | $4035 | $11.14K | $11.57K | $12.68K | $7007 | — | — | — | — | — | — | — | — | |
| $13.24M | -$12M | -$11.05M | -$8.57M | -$14.07M | -$10.13M | -$13.85M | -$12.94M | -$14.68M | -$11.16M | -$10.87M | -$8.85M | -$9.2M | -$4.03M | -$10.96M | -$17.73M | -$20.19M | -$20.37M | -$21.92M | -$48.9M | -$35.69M | -$25.69M | — | — | — | — | |
| — | -2928.78% | — | -857.15% | — | -251% | — | — | — | — | — | — | — | — | -1365.76% | — | — | — | — | — | — | — | — | — | — | — | |
| -$14.68M | — | — | — | — | — | — | — | — | — | — | — | -$9.2M | -$4.03M | -$10.96M | -$17.73M | -$20.19M | -$20.37M | — | — | — | — | — | — | — | — | |
| -$10.75M | -$11.99M | -$11.07M | -$8.57M | -$14.09M | -$10.14M | -$13.85M | -$12.94M | -$14.67M | -$11.16M | -$10.86M | -$8.85M | -$9.22M | -$4.04M | -$10.97M | -$17.74M | -$20.18M | -$20.4M | -$21.82M | -$48.99M | -$35.72M | -$25.71M | -$48.27M | -$6.21M | -$6.93M | -$1.79M | |
| USD/shares | — | -$0.24 | -$0.23 | -$0.17 | -$0.29 | -$0.21 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| USD/shares | — | -$0.24 | -$0.23 | -$0.17 | -$0.29 | -$0.21 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | 49.06M | 49.05M | 49.05M | 49.05M | 48.6M | 44.41M | 43.16M | 41.12M | 35.14M | 32.99M | 26.58M | 24.07M | 20.7M | 16.52M | 14.81M | — | — | — | — | — | — | — | — | — | — |
| shares | — | 49.06M | 49.05M | 49.05M | 49.05M | 48.6M | 44.41M | 43.16M | 41.12M | 35.14M | 32.99M | 26.58M | 24.07M | 20.7M | 16.52M | 14.81M | — | — | — | — | — | — | — | — | — | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2009–FY2012: $186.28K in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.33×
EV/EBIT
—
Peer median 12.10×
P/E (TTM)
—
Peer median 10.33×
Peer medians compare against the 294 similar-size Biotechnology companies (of 517 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2023 |
|---|---|---|
| Reportable Segment Aggregation Before Other Operating Segment | $409,657 | $1,000,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment Aggregation Before Other Operating Segment | -$13,283,002 | -$12,675,331 | -$9,900,265 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2023 |
|---|---|---|
| Reportable Segment Aggregation Before Other Operating Segment | -3242.5% | -990% |
Key facts
CIK
1226616
CUSIP
58468P206
13F (30d)
28 filings
28 filers
Visit website
Investor relations